Pulmonx (LUNG) Free Cash Flow (2019 - 2025)

Pulmonx (LUNG) has 7 years of Free Cash Flow data on file, last reported at -$8.1 million in Q3 2025.

• Free Cash Flow for Q3 2025 came in at -$8.1 million, up 2.84% year-over-year; the trailing twelve-month figure through Dec 2025 was -$25.3 million (up 20.31% YoY), and the FY2024 annual result was -$31.8 million, up 15.79% from the prior year.
• Free Cash Flow slipped to -$8.1 million in Q3 2025 per LUNG's latest filing, from -$3.7 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$3.7 million in Q2 2025 and troughed at -$15.6 million in Q1 2022.
• A 5-year average of -$9.8 million and a median of -$9.9 million in 2022 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2021 and 2024: Free Cash Flow tumbled 69.56% in 2021, then jumped 33.52% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$11.8 million in 2021, then advanced by 23.29% to -$9.1 million in 2022, then increased by 7.01% to -$8.5 million in 2023, then jumped by 33.52% to -$5.6 million in 2024, then sank by 44.67% to -$8.1 million in 2025.
• Business Quant data shows LUNG's Free Cash Flow at -$8.1 million in Q3 2025, -$3.7 million in Q2 2025, and -$13.5 million in Q1 2025.